Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OP-724 in Advanced Primary Biliary Cholangitis
NCT04047160Phase 1Completed
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of foscenvivint in primary biliary cholangitis (PBC) (2 arms). Primary endpoint: Occurrence Rate of Serious Adverse Events. Started Aug 2019; status: completed.
02
Drugs
foscenvivint
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04047160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047160.